Method and composition for diagnosis of melanocytic lesions

a technology of melanocytic lesions and compositions, applied in the field of melanocytic antigens and antibodies against melanomaassociated antigens, can solve the problems of limiting the usefulness of nki/c3 antibody in the diagnosis of melanocytic lesions, anti-s100 antibodies are notoriously unspecific, etc., and achieve the effect of increasing the solubility of compounds and facilitating the processing of active compounds

a technology of melanocytic lesions and compositions, applied in the field of melanocytic antigens and antibodies against melanomaassociated antigens, can solve the problems of limiting the usefulness of nki/c3 antibody in the diagnosis of melanocytic lesions, anti-s100 antibodies are notoriously unspecific, etc., and achieve the effect of increasing the solubility of compounds and facilitating the processing of active compounds

US20050227303A1Inactive Publication Date: 2005-10-13ONCOMAX ACQUISITION CORP
14 Cites 25 Cited by

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Method and composition for diagnosis of melanocytic lesions

Examples

Experimental program
Comparison scheme
Effect test

Embodiment Construction

[0077] A. Preparation of SM5-1 Antibody

[0078] SM5-1 antibody is selected from a panel of monoclonal antibodies generated by using a subtractive imnunization protocol as previously described in Williams et al., (1992) Biotechniques 12:842-8477, and Brooks et al., (1993) J. Cell Biol. 22:1351-1359, both of which are incorporated by reference herein.

[0079] Briefly, mice were immunized with human melanoma cell line SMMU-1, which was obtained from the primary melanoma of a patient (Guo et al., (1994) Cancer Res. 54:561-1565, incorporated by reference herein). Next, the mice were treated with cyclophosphamide to abrogate activated B cells that produce antibody against epitopes expressed by the primary melanoma. The mice were then immunized with human melanoma cell line SMMU-2, which was obtained from the metastatic lesion of the same patient. The splenocytes from the mice were used for making hybridomas using standard techniques. Köhler G, Milstein C: Derivation of specific antibody pro...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
apparent molecular weightaaaaaaaaaa
spectrumaaaaaaaaaa
antibody titersaaaaaaaaaa
Login to View More

Abstract

This invention relates to monoclonal antibodies that recognize an antigen specific to melanocytic lesions. These antibodies are useful in methods of isolating melanoma cells and diagnosing melanocytic lesions. These antibodies are also useful for immunotherapy against melanoma.

Description

I. FIELD OF THE INVENTION [0001] This invention relates to melanoma-associated antigens, antibodies against melanoma-associated antigens, and diagnostic and therapeutic methods concerning melanoma. II. BACKGROUND OF THE INVENTION [0002] Human malignant melanoma usually starts as harmless moles that undergo radial to invasive growth and end in the destructive stage of metastatic melanoma. Melanoma usually resists chemotherapy and radiotherapy. Surgery is the most effective treatment. Early diagnosis is required for surgery to be effective, which is unfortunately hampered by the lack of markers that are sensitive and specific for melanoma. [0003] The commonly used antibodies for immuno-histochemical diagnosis of melanoma are HMB-45, anti-S-100 and NKI / C3 (for a review, please see Smoller B R, “Immunohistochemistry in the Diagnosis of Melanocytic Neoplasms”, in PATHOLOGY: State of the Art Reviews, 2:371-383, 1994). [0004] HMB-45 has been shown to react with the melanoma-associated anti...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
13 Oct 2005
Publication
US20050227303A1
IPC
C07H21/04; C07K16/30; C12N15/09; C12Q1/68; G01N33/574
CPC
C07K16/3053
Inventors
GUO, YAJUN; MA, JING